The UQCRQ (Ubiquinol-Cytochrome C Reductase Core Protein Q) gene encodes a core component of mitochondrial complex III (cytochrome bc1 complex), also known as ubiquinol-cytochrome c reductase. This protein is essential for the mitochondrial electron transport chain and ATP production. Complex III is crucial for cellular energy metabolism, and its dysfunction is implicated in various neurodegenerative diseases.
UQCRQ encodes a small mitochondrial protein (approximately 174 amino acids) that is a core component of complex III:
The complex III dimer consists of multiple subunits, with UQCRQ being one of the small core proteins that provide structural stability[2].
Complex III (ubiquinol-cytochrome c reductase) performs a critical step in the mitochondrial respiratory chain:
Mitochondria generate the majority of cellular ATP through oxidative phosphorylation. Complex III is essential for:
Complex III is a significant source of mitochondrial ROS. Under normal conditions, controlled ROS production serves as signaling molecules. The Q cycle in complex III is the primary site of superoxide production[3].
Mitochondrial dysfunction is a central feature of Parkinson's disease (PD). Complex III impairment in dopaminergic neurons leads to:
Genetic variants in mitochondrial complex III genes, including UQCRQ, have been associated with PD risk[4][5].
In Alzheimer's disease (AD), mitochondrial dysfunction precedes classic pathological changes:
Mitochondrial dysfunction is a hallmark of ALS:
Mitochondrial complex III defects have been reported in Huntington's disease (HD):
UQCRQ is ubiquitously expressed, with highest levels in:
Targeting mitochondrial complex III offers therapeutic potential:
Iwata S, et al. Structure of cytochrome bc1 complex: protonmotive pathway and binding sites. Science. 1998. ↩︎ ↩︎ ↩︎
Hunte C, et al. Protonmotive pathway and mechanism in cytochrome bc1 complexes. Biochim Biophys Acta. 2005. ↩︎ ↩︎ ↩︎
Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009. ↩︎ ↩︎
Schapira AH. Mitochondrial dysfunction in Parkinson's disease. Cell Death Differ. 2007. ↩︎ ↩︎ ↩︎
Pyle A, et al. Mitochondrial complex I activity in Parkinson's disease: a case-control study. Neurology. 2015. ↩︎ ↩︎
Manczak M, et al. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006. ↩︎ ↩︎
Cozzolino M, et al. Mitochondria: new frontiers in ALS pathogenesis and therapeutic targets. Mol Neurobiol. 2014. ↩︎
Tunez I, et al. Mitochondrial dysfunction in Huntington's disease: pathogenesis and therapeutic opportunities. Free Radic Biol Med. 2013. ↩︎ ↩︎
Ko HS, et al. Gene therapy for mitochondrial disorders: recent advances. Mol Ther. 2015. ↩︎